Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.

<h4>Background</h4> <p>Negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialisation, speech and movement. When persistent, they are held to account for much of the poor functional outcomes associated with schizophrenia. There are...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser: Barnes, T, Leeson, V, Paton, C, Costelloe, C, Simon, J, Kiss, N, Osborn, D, Killaspy, H, Craig, T, Lewis, S, Keown, P, Ismail, S, Crawford, M, Baldwin, D, Lewis, G, Geddes, J, Kumar, M, Pathak, R, Taylor, S
Format: Journal article
Sprache:English
Veröffentlicht: National Institute for Health Research 2016
_version_ 1826281459434913792
author Barnes, T
Leeson, V
Paton, C
Costelloe, C
Simon, J
Kiss, N
Osborn, D
Killaspy, H
Craig, T
Lewis, S
Keown, P
Ismail, S
Crawford, M
Baldwin, D
Lewis, G
Geddes, J
Kumar, M
Pathak, R
Taylor, S
author_facet Barnes, T
Leeson, V
Paton, C
Costelloe, C
Simon, J
Kiss, N
Osborn, D
Killaspy, H
Craig, T
Lewis, S
Keown, P
Ismail, S
Crawford, M
Baldwin, D
Lewis, G
Geddes, J
Kumar, M
Pathak, R
Taylor, S
author_sort Barnes, T
collection OXFORD
description <h4>Background</h4> <p>Negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialisation, speech and movement. When persistent, they are held to account for much of the poor functional outcomes associated with schizophrenia. There are currently no approved pharmacological treatments. While the available evidence suggests that a combination of antipsychotic and antidepressant medication may be effective in treating negative symptoms, it is too limited to allow any firm conclusions.</p> <h4>Objective</h4> <p>To establish the clinical effectiveness and cost-effectiveness of augmentation of antipsychotic medication with the antidepressant citalopram for the management of negative symptoms in schizophrenia.</p> <h4>Design</h4> <p>A multicentre, double-blind, individually randomised, placebo-controlled trial with 12-month follow-up</p> <h4>Setting</h4> <p>Adult psychiatric services, treating people with schizophrenia.</p> <h4>Participants</h4> <p>Inpatients or outpatients with schizophrenia, on continuing, stable antipsychotic medication, with persistent negative symptoms at a criterion level of severity.</p> <h4>Interventions</h4> <p>Eligible participants were randomised 1 : 1 to treatment with either placebo (one capsule) or 20 mg of citalopram per day for 48 weeks, with the clinical option at 4 weeks to increase the daily dosage to 40 mg of citalopram or two placebo capsules for the remainder of the study.</p> <h4>Main Outcome Measures</h4> <p>The primary outcomes were quality of life measured at 12 and 48 weeks assessed using the Heinrich’s Quality of Life Scale, and negative symptoms at 12 weeks measured on the negative symptom subscale of the Positive and Negative Syndrome Scale.</p> <h4>Results</h4> <p>No therapeutic benefit in terms of improvement in quality of life or negative symptoms was detected for citalopram over 12 weeks or at 48 weeks, but secondary analysis suggested modest improvement in the negative symptom domain, avolition/amotivation, at 12 weeks (mean difference –1.3, 95% confidence interval–2.5 to–0.09). There were no statistically significant differences between the two treatment arms over 48-week follow-up in either the health economics outcomes or costs, and no differences in the frequency or severity of adverse effects, including corrected QT interval prolongation.</p> <h4>Limitations</h4> <p>The trial under-recruited, partly because cardiac safety concerns about citalopram were raised, with the 62 participants recruited falling well short of the target recruitment of 358. Although this was the largest sample randomised to citalopram in a randomised controlled trial of antidepressant augmentation for negative symptoms of schizophrenia and had the longest follow-up, the power of statistical analysis to detect significant differences between the active and placebo groups was limited.</p> <h4>Conclusion</h4> <p>Although adjunctive citalopram did not improve negative symptoms overall, there was evidence of some positive effect on avolition/amotivation, recognised as a critical barrier to psychosocial rehabilitation and achieving better social and community functional outcomes. Comprehensive assessment of side-effect burden did not identify any serious safety or tolerability issues. The addition of citalopram as a long-term prescribing strategy for the treatment of negative symptoms may merit further investigation in larger studies.</p> <h4>Future Work</h4> <p>Further studies of the viability of adjunctive antidepressant treatment for negative symptoms in schizophrenia should include appropriate safety monitoring and use rating scales that allow for evaluation of avolition/amotivation as a discrete negative symptom domain. Overcoming the barriers to recruiting an adequate sample size will remain a challenge.</p>
first_indexed 2024-03-07T00:29:07Z
format Journal article
id oxford-uuid:7f27c12f-a9cf-43dd-8626-23e1711fa97d
institution University of Oxford
language English
last_indexed 2024-03-07T00:29:07Z
publishDate 2016
publisher National Institute for Health Research
record_format dspace
spelling oxford-uuid:7f27c12f-a9cf-43dd-8626-23e1711fa97d2022-03-26T21:15:01ZAntidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7f27c12f-a9cf-43dd-8626-23e1711fa97dEnglishSymplectic Elements at OxfordNational Institute for Health Research2016Barnes, TLeeson, VPaton, CCostelloe, CSimon, JKiss, NOsborn, DKillaspy, HCraig, TLewis, SKeown, PIsmail, SCrawford, MBaldwin, DLewis, GGeddes, JKumar, MPathak, RTaylor, S <h4>Background</h4> <p>Negative symptoms of schizophrenia represent deficiencies in emotional responsiveness, motivation, socialisation, speech and movement. When persistent, they are held to account for much of the poor functional outcomes associated with schizophrenia. There are currently no approved pharmacological treatments. While the available evidence suggests that a combination of antipsychotic and antidepressant medication may be effective in treating negative symptoms, it is too limited to allow any firm conclusions.</p> <h4>Objective</h4> <p>To establish the clinical effectiveness and cost-effectiveness of augmentation of antipsychotic medication with the antidepressant citalopram for the management of negative symptoms in schizophrenia.</p> <h4>Design</h4> <p>A multicentre, double-blind, individually randomised, placebo-controlled trial with 12-month follow-up</p> <h4>Setting</h4> <p>Adult psychiatric services, treating people with schizophrenia.</p> <h4>Participants</h4> <p>Inpatients or outpatients with schizophrenia, on continuing, stable antipsychotic medication, with persistent negative symptoms at a criterion level of severity.</p> <h4>Interventions</h4> <p>Eligible participants were randomised 1 : 1 to treatment with either placebo (one capsule) or 20 mg of citalopram per day for 48 weeks, with the clinical option at 4 weeks to increase the daily dosage to 40 mg of citalopram or two placebo capsules for the remainder of the study.</p> <h4>Main Outcome Measures</h4> <p>The primary outcomes were quality of life measured at 12 and 48 weeks assessed using the Heinrich’s Quality of Life Scale, and negative symptoms at 12 weeks measured on the negative symptom subscale of the Positive and Negative Syndrome Scale.</p> <h4>Results</h4> <p>No therapeutic benefit in terms of improvement in quality of life or negative symptoms was detected for citalopram over 12 weeks or at 48 weeks, but secondary analysis suggested modest improvement in the negative symptom domain, avolition/amotivation, at 12 weeks (mean difference –1.3, 95% confidence interval–2.5 to–0.09). There were no statistically significant differences between the two treatment arms over 48-week follow-up in either the health economics outcomes or costs, and no differences in the frequency or severity of adverse effects, including corrected QT interval prolongation.</p> <h4>Limitations</h4> <p>The trial under-recruited, partly because cardiac safety concerns about citalopram were raised, with the 62 participants recruited falling well short of the target recruitment of 358. Although this was the largest sample randomised to citalopram in a randomised controlled trial of antidepressant augmentation for negative symptoms of schizophrenia and had the longest follow-up, the power of statistical analysis to detect significant differences between the active and placebo groups was limited.</p> <h4>Conclusion</h4> <p>Although adjunctive citalopram did not improve negative symptoms overall, there was evidence of some positive effect on avolition/amotivation, recognised as a critical barrier to psychosocial rehabilitation and achieving better social and community functional outcomes. Comprehensive assessment of side-effect burden did not identify any serious safety or tolerability issues. The addition of citalopram as a long-term prescribing strategy for the treatment of negative symptoms may merit further investigation in larger studies.</p> <h4>Future Work</h4> <p>Further studies of the viability of adjunctive antidepressant treatment for negative symptoms in schizophrenia should include appropriate safety monitoring and use rating scales that allow for evaluation of avolition/amotivation as a discrete negative symptom domain. Overcoming the barriers to recruiting an adequate sample size will remain a challenge.</p>
spellingShingle Barnes, T
Leeson, V
Paton, C
Costelloe, C
Simon, J
Kiss, N
Osborn, D
Killaspy, H
Craig, T
Lewis, S
Keown, P
Ismail, S
Crawford, M
Baldwin, D
Lewis, G
Geddes, J
Kumar, M
Pathak, R
Taylor, S
Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
title Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
title_full Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
title_fullStr Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
title_full_unstemmed Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
title_short Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial.
title_sort antidepressant controlled trial for negative symptoms in schizophrenia actions a double blind placebo controlled randomised clinical trial
work_keys_str_mv AT barnest antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT leesonv antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT patonc antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT costelloec antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT simonj antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT kissn antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT osbornd antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT killaspyh antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT craigt antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT lewiss antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT keownp antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT ismails antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT crawfordm antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT baldwind antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT lewisg antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT geddesj antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT kumarm antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT pathakr antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial
AT taylors antidepressantcontrolledtrialfornegativesymptomsinschizophreniaactionsadoubleblindplacebocontrolledrandomisedclinicaltrial